The association between TP53 Arg72Pro polymorphism and lung cancer susceptibility: Evidence from 30,038 subjects

Lung

Volumn 191, Issue 4, 2013, Pages 369-377

  Qiao, Qian ^a,b   Hu, Weiguo ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Arg72Pro; Lung cancer; Meta analysis; TP53

Indexed keywords

PROTEIN P53;

ARTICLE; ASIAN; CANCER STAGING; CANCER SUSCEPTIBILITY; CAUCASIAN; CONTROLLED STUDY; ETHNICITY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HETEROZYGOTE; HISTOLOGY; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; META ANALYSIS; POPULATION RESEARCH; PRIORITY JOURNAL; SMOKING;

EID: 84880813231     PISSN: 03412040     EISSN: 14321750     Source Type: Journal    
DOI: 10.1007/s00408-013-9461-9     Document Type: Article

References (68)

1. Lichtenstein P, Holm N, Verkasalo P, Iliadou A, Kaprio J, Koskenvuo M, Pukkala E, Skytthe A, Hemminki K (2000) Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 343:78
2. Zhang D, Chen C, Li Y, Fu X, Xie Y, Li Y, Huang Y (2012) Cx31. 1 acts as a tumour suppressor in non-small cell lung cancer (NSCLC) cell lines through inhibition of cell proliferation and metastasis. J Cell Mol Med 16:1047-1059
3. Zhang D, Chen C, Fu X, Gu S, Mao Y, Xie Y, Huang Y, Li Y (2008) A meta-analysis of DNA repair gene XPC polymorphisms and cancer risk. J Hum Genet 53:18-33
4. Oren M (2003) Decision making by p53: life, death and cancer. Cell Death Differ 10:431-442
5. Lane D (2004) p53 from pathway to therapy. Carcinogenesis 25:1077
6. Vogelstein B, Lane D, Levine A (2000) Surfing the p53 network. Nature 408:307-310
7. Murphy M (2006) Polymorphic variants in the p53 pathway. Cell Death Differ 13:916-920
8. Pietsch E, Humbey O, Murphy M (2006) Polymorphisms in the p53 pathway. Oncogene 25:1602-1611
9. Dumont P, Leu JIJ, Della Pietra AC, George DL, Murphy M (2003) The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33:357-365
10. Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G (1999) Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 19:1092-1100
11. Pim D, Banks L (2004) p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer 108:196-199
12. Cavallone L, Arcand SL, Maugard C, Ghadirian P, Mes-Masson AM, Provencher D, Tonin PN (2008) Haplotype analysis of TP53 polymorphisms, Arg72Pro and Ins16, in BRCA1 and BRCA2 mutation carriers of French Canadian descent. BMC Cancer 8:96
13. Woolf B (1955) On estimating the relation between blood group and disease. Ann Hum Genet 19:251-253
14. Lau J, Ioannidis JP, Schmid CH (1997) Quantitative synthesis in systematic reviews. Ann Intern Med 127:820-826
15. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629-634
16. Weston A, Ling-Cawley HM, Caporaso NE, Bowman ED, Hoover RN, Trump BF, Harris CC (1994) Determination of the allelic frequencies of an L-myc and a p53 polymorphism in human lung cancer. Carcinogenesis 15:583
17. Miller DP, Liu G, De Vivo I, Lynch TJ, Wain JC, Su L, Christiani DC (2002) Combinations of the variant genotypes of GSTP1, GSTM1, and p53 are associated with an increased lung cancer risk. Cancer Res 62:2819
18. Papadakis ED, Soulitzis N, Spandidos DA (2002) Association of p53 codon 72 polymorphism with advanced lung cancer: the Arg allele is preferentially retained in tumours arising in Arg/Pro germline heterozygotes. Br J Cancer 87:1013-1018
19. Wu X, Zhao H, Amos CI, Shete S, Makan N, Hong WK, Kadlubar FF, Spitz MR (2002) p53 genotypes and haplotypes associated with lung cancer susceptibility and ethnicity. J Natl Cancer Inst 94:681
20. Nadji SA, Mahmoodi M, Ziaee AA, Naghshvar F, Torabizadeh J, Yahyapour Y, Nategh R, Mokhtari-Azad T (2007) An increased lung cancer risk associated with codon 72 polymorphism in the TP53 gene and human papillomavirus infection in Mazandaran province, Iran. Lung Cancer 56:145-151
21. Biros E, Kalina I, Biros I, Kohut A, Bogyiova E, Salagovic J, Stubna J (2001) Polymorphism of the p53 gene within the codon 72 in lung cancer patients. Neoplasma 48:407-411
22. Fan R, Wu MT, Miller D, Wain JC, Kelsey KT, Wiencke JK, Christiani DC (2000) The p53 codon 72 polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev 9:1037
23. Murata M, Tagawa M, Kimura M, Kimura H, Watanabe S, Saisho H (1996) Analysis of a germ line polymorphism of the p53 gene in lung cancer patients; discrete results with smoking history. Carcinogenesis 17:261
24. Biro E, Kalina I, Kohút A (2001) Germ line polymorphisms of the tumor suppressor gene p53 and lung cancer. Lung Cancer 31:157-162
25. Murata M, Tagawa M, Kimura H, Kakisawa K, Shirasawa H, Fujisawa T (1998) Correlation of the mutation of p53 gene and the polymorphism at codon 72 in smoking-related non-small cell lung cancer patients. Int J Oncol 12:577
26. Weston A, Perrin LS, Forrester K, Hoover RN, Trump BF, Harris CC, Caporaso NE (1992) Allelic frequency of a p53 polymorphism in human lung cancer. Cancer Epidemiol Biomarkers Prev 1:481
27. Kawajiri K, Nakachi K, Imai K, Watanabe J, Hayashi SI (1993) Germ line polymorphisms of p53 and CYP1A1 genes involved in human lung cancer. Carcinogenesis 14:1085
28. Birgander R, Sjlander A, Rannug A, Alexandrie AK, Sundberg MI, Seideg J, Tornling G, Beckman G, Beckman L (1995) P53 polymorphisms and haplotypes in lung cancer. Carcinogenesis 16:2233
29. Jin X, Wu X, Roth JA, Amos CI, King TM, Branch C, Honn SE, Spitz MR (1995) Higher lung cancer risk for younger African-Americans with the Pro/Pro p53 genotype. Carcinogenesis 16:2205
30. To-Figueras J, Gene M, Gomez-Catalan J, Galan C, Firvida J, Fuentes M, Rodamilans M, Huguet E, Estape J, Corbella J (1996) Glutathione-S-Transferase M1 and codon 72 p53 polymorphisms in a northwestern Mediterranean population and their relation to lung cancer susceptibility. Cancer Epidemiol Biomarkers Prev 5:337
31. Wang YC, Chen CY, Chen SK, Chang YY, Lin P (1999) p53 codon 72 polymorphism in Taiwanese lung cancer patients: association with lung cancer susceptibility and prognosis. Clin Cancer Res 5:129
32. Pierce LM, Sivaraman L, Chang W, Lum A, Donlon T, Seifried A, Wilkens LR, Lau AF, Le Marchand L (2000) Relationships of TP53 codon 72 and HRAS1 polymorphisms with lung cancer risk in an ethnically diverse population. Cancer Epidemiol Biomarkers Prev 9:1199
33. Liu G, Miller DP, Zhou W, Thurston SW, Fan R, Xu LL, Lynch TJ, Wain JC, Su L, Christiani DC (2001) Differential association of the codon 72 p53 and GSTM1 polymorphisms on histological subtype of non-small cell lung carcinoma. Cancer Res 61:8718
34. Hiraki A, Matsuo K, Hamajima N, Ito H, Hatooka S, Suyama M, Mitsudomi T, Tajima K (2003) Different risk relations with smoking for non-small-cell lung cancer: comparison of TP53 and TP73 genotypes. Asian Pac J Cancer Prev 4:107-112
35. Irarrázabal CE, Rojas C, Aracena R, Márquez C, Gil L (2003) Chilean pilot study on the risk of lung cancer associated with codon 72 polymorphism in the gene of protein p53. Toxicol Lett 144:69-76
36. Zhang JH, Li Y, Wang R, Wen DG, Wu ML, He M (2003) p53 gene polymorphism with susceptibility to esophageal cancer and lung cancer in Chinese population. Zhonghua Zhong Liu Za Zhi [Chinese J Oncol] 25:365
37. Jain N, Singh V, Hedau S, Kumar S, Daga MK, Dewan R, Murthy NS, Husain SA, Das BC (2005) Infection of human papillomavirus type 18 and p53 codon 72 polymorphism in lung cancer patients from India. Chest 128:3999
38. Sakiyama T, Kohno T, Mimaki S, Ohta T, Yanagitani N, Sobue T, Kunitoh H, Saito R, Shimizu K, Hirama C (2005) Association of amino acid substitution polymorphisms in DNA repair genes TP53, POLI, REV1 and LIG4 with lung cancer risk. Int J Cancer 114:730-737
39. Szymanowska A, Jassem E, Dziadziuszko R, Borg A, Limon J, Kobierska-Gulida G, Rzyman W, Jassem J (2006) Increased risk of non-small cell lung cancer and frequency of somatic TP53 gene mutations in Pro72 carriers of TP53 Arg72Pro polymorphism. Lung Cancer 52:9-14
40. Zhang X, Miao X, Guo Y, Tan W, Zhou Y, Sun T, Wang Y, Lin D (2006) Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer. Hum Mutat 27:110-117
41. Giuliani L, Jaxmar T, Casadio C, Gariglio M, Manna A, D'Antonio D, Syrjanen K, Favalli C, Ciotti M (2007) Detection of oncogenic viruses (SV40, BKV, JCV, HCMV, HPV) and p53 codon 72 polymorphism in lung carcinoma. Lung Cancer 57:273-281
42. Mechanic LE, Bowman ED, Welsh JA, Khan MA, Hagiwara N, Enewold L, Shields PG, Burdette L, Chanock S, Harris CC (2007) Common genetic variation in TP53 is associated with lung cancer risk and prognosis in African Americans and somatic mutations in lung tumors. Cancer Epidemiol Biomarkers Prev 16:214
43. Popanda O, Edler L, Waas P, Schattenberg T, Butkiewicz D, Muley T, Dienemann H, Risch A, Bartsch H, Schmezer P (2007) Elevated risk of squamous-cell carcinoma of the lung in heavy smokers carrying the variant alleles of the TP53 Arg72Pro and p21 Ser31Arg polymorphisms. Lung Cancer 55:25-34
44. Honma HN, De Capitani EM, Perroud MW Jr, Barbeiro AS, Toro IFC, Costa DB, Lima CSP, Zambon L (2008) Influence of p53 codon 72 exon 4, GSTM1, GSTT1 and GSTP1*B polymorphisms in lung cancer risk in a Brazilian population. Lung Cancer 61:152-162
45. Jung HY, Whang YM, Sung JS, Shin HD, Park BL, Kim JS, Shin SW, Seo HY, Seo JH, Kim YH (2008) Association study of TP53 polymorphisms with lung cancer in a Korean population. J Hum Genet 53:508-514
46. Fernández-Rubio A, López-Cima MF, González-Arriaga P, García-Castro L, Pascual T, Marrón MG, Tardón A (2008) The TP53 Arg72Pro polymorphism and lung cancer risk in a population of Northern Spain. Lung Cancer 61:309-316
47. Sreeja L, Syamala V, Raveendran PB, Santhi S, Madhavan J, Ankathil R (2008) p53 Arg72Pro polymorphism predicts survival outcome in lung cancer patients in Indian population. Cancer Invest 26:41-46
48. Cáceres DD, Qui ones LA, Schroeder JC, Gil LD, Irarrázabal CE (2009) Association Between p53 codon 72 genetic polymorphism and tobacco use and lung cancer risk. Lung 187:110-115
49. Klinchid J, Chewaskulyoung B, Saeteng S, Lertprasertsuke N, Kasinrerk W, Cressey R (2009) Effect of combined genetic polymorphisms on lung cancer risk in northern Thai women. Cancer Genet Cytogenet 195:143-149
50. Sobti RC, Kaur P, Kaur S, Janmeja AK, Jindal SK, Kishan J, Raimondi S (2009) Impact of interaction of polymorphic forms of p53 Codon 72 and N-acetylation gene (NAT2) on the risk of lung cancer in the North Indian population. DNA Cell Biol 28:443-449
51. Chua HW, Ng D, Choo S, Lum SS, Li H, Soh LY, Sabapathy K, Seow A (2010) Effect of MDM 2 SNP 309 and p 53 codon 72 polymorphisms on lung cancer risk and survival among non-smoking Chinese women in Singapore. BMC Cancer 10:88
52. Ihsan R, Devi TR, Yadav DS, Mishra AK, Sharma J, Zomawia E, Verma Y, Phukan R, Mahanta J, Kataki AC (2011) Investigation on the role of p53 codon 72 polymorphism and interactions with tobacco, Betel Quid, and alcohol in susceptibility to cancers in a high-risk population from North East India. DNA Cell Biol 30:317-324
53. Su L, Sai Y, Fan R, Thurston SW, Miller DP, Zhou W, Wain JC, Lynch TJ, Liu G, Christiani DC (2003) P53 (codon 72) and P21 (codon 31) polymorphisms alter in vivo mRNA expression of p21. Lung Cancer 40:259-266
54. Hung RJ, Boffetta P, Canzian F, Moullan N, Szeszenia-Dabrowska N, Zaridze D, Lissowska J, Rudnai P, Fabianova E, Mates D (2006) Sequence variants in cell cycle control pathway, X-ray exposure, and lung cancer risk: a multicenter case-control study in Central Europe. Cancer Res 66:8280-8286
55. Cherdyntseva N, Gervas P, Litvyakov N, Stakcheeva M, Ponomaryeva A, Dobrodeev AY, Denisov E, Belyavskaya V, Choinzonov E (2010) Age-related function of tumor suppressor gene TP53: contribution to cancer risk and progression. Exp Oncol 32:205-208
56. Kiyohara C, Horiuchi T, Miyake Y, Takayama K, Nakanishi Y (2010) Cigarette smoking, TP53 Arg72Pro, TP53BP1 Asp353Glu and the risk of lung cancer in a Japanese population. Oncol Rep 23:1361
57. Piao JM, Kim HN, Song HR, Kweon SS, Choi JS, Yun WJ, Kim YC, Oh IJ, Kim KS, Shin MH (2011) p53 codon 72 polymorphism and the risk of lung cancer in a Korean population. Lung Cancer 73:264-267
58. Liu D, Wang F, Guo X, Wang Q, Wang W, Xu H, Xu G (2012) Association between p53 codon 72 genetic polymorphisms and tobacco use and lung cancer risk in a Chinese population. Mol Biol Rep 40:1-5
59. Cheng Z, Wang W, Song YN, Kang Y, Xia J (2012) hOGG1, p53 genes, and smoking interactions are associated with the development of lung cancer. Asian Pac J Cancer Prev 13(5):1803-1808
60. Chen C, Fu X, Zhang D, Li Y, Xie Y, Li Y, Huang Y (2011) Varied pathways of stage IA lung adenocarcinomas discovered by integrated gene expression analysis. Int J Biol Sci 7:551
61. Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991) p53 mutations in human cancers. Science 253:49-53
62. Dumont P, Leu J, Della Pietra A, George D, Murphy M (2003) The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nature Genet 33:357-365
63. Dai S, Mao C, Jiang L, Wang G, Cheng H (2009) P53 polymorphism and lung cancer susceptibility: a pooled analysis of 32 case-control studies. Hum Genet 125:633-638
64. Li Y, Qiu LX, Shen XK, Lv XJ, Qian XP, Song Y (2009) A meta-analysis of TP53 codon 72 polymorphism and lung cancer risk: evidence from 15,857 subjects. Lung Cancer 66:15-21
65. Yan L, Zhang D, Chen C, Mao Y, Xie Y, Li Y, Huang Y, Han B (2009) TP53 Arg72Pro polymorphism and lung cancer risk: a meta-analysis. Int J Cancer 125:2903-2911
66. Weston A, Godbold JH (1997) Polymorphisms of H-ras-1 and p53 in breast cancer and lung cancer: a meta-analysis. Environ Health Perspect 105:919
67. Rodin S, Rodin A (2000) Human lung cancer and p53: the interplay between mutagenesis and selection. Proc Natl Acad Sci USA 97:12244
68. Salanti G, Sanderson S, Higgins JP (2005) Obstacles and opportunities in meta-analysis of genetic association studies. Genet Med 7:13-20